The Journal of Thoracic and Cardiovascular Surgery
Volume 136, Issue 5 , Pages 1149-1155, November 2008

Influence of preoperative renal dysfunction on one-year bypass graft patency and two-year outcomes in patients undergoing coronary artery bypass surgery

  • Rajendra H. Mehta, MD, MS

      Affiliations

    • Duke Clinical Research Institute and Duke University Medical Center, Durham, NC
    • Corresponding Author InformationAddress for reprints: Rajendra H. Mehta, MD, MS, Box 17969, Duke Clinical Research Institute, Durham, NC 27715.
  • ,
  • Gail E. Hafley, MS

      Affiliations

    • Duke Clinical Research Institute and Duke University Medical Center, Durham, NC
  • ,
  • C. Michael Gibson, MD

      Affiliations

    • Beth Israel Deaconess Medical Center, Boston, Mass
  • ,
  • Robert A. Harrington, MD

      Affiliations

    • Duke Clinical Research Institute and Duke University Medical Center, Durham, NC
  • ,
  • Eric D. Peterson, MD, MPH

      Affiliations

    • Duke Clinical Research Institute and Duke University Medical Center, Durham, NC
  • ,
  • Michael J. Mack, MD

      Affiliations

    • Medical City Hospital, Dallas, Tex
  • ,
  • Nicholas T. Kouchoukos, MD

      Affiliations

    • Missouri Baptist Medical Center, St Louis, Mo
  • ,
  • Robert M. Califf, MD

      Affiliations

    • Duke Clinical Research Institute and Duke University Medical Center, Durham, NC
  • ,
  • T. Bruce Ferguson Jr., MD

      Affiliations

    • East Carolina University, Greenville, NC
  • ,
  • John H. Alexander, MD, MHS

      Affiliations

    • Duke Clinical Research Institute and Duke University Medical Center, Durham, NC
  • ,
  • Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT)-IV Investigators

Received 21 August 2007; received in revised form 12 December 2007; accepted 19 February 2008. published online 28 August 2008.

Objective

Limited information exists on the impact of preoperative renal dysfunction on internal thoracic artery and saphenous vein graft failure and 2-year clinical outcomes in patients undergoing coronary artery bypass surgery.

Methods

We studied the impact of preoperative renal dysfunction (creatinine clearance < 60 mL/min) on 1-year internal thoracic artery and saphenous vein graft failure (defined as ≥ 75% angiographic stenosis) and 2-year clinical events (death; death or myocardial infarction; and death, myocardial infarction, or revascularization) in 3014 patients undergoing coronary artery bypass surgery enrolled in the Project of Ex-vivo Vein Graft Engineering via Transfection-IV study.

Results

Of 2973 patients (98.6%) with preoperative measurement of renal function, 440 (14.8%) had renal dysfunction. Most baseline comorbidities were higher in these patients. Two-year clinical events were higher in patients with preoperative renal dysfunction (adjusted death, myocardial infarction, or revascularization, hazard ratio 1.21, 95% confidence interval 0.97–1.50; adjusted death or myocardial infarction, hazard ratio 1.35, 95% confidence interval 1.05–1.74; adjusted death, hazard ratio 1.47, 95% confidence interval 0.98–2.21). However, saphenous vein graft (odds ratio 1.02, 95% confidence interval 0.79–1.33) and internal thoracic artery (odds ratio 0.76, 95% confidence interval 0.40–1.44) failure were similar in the 2 groups.

Conclusion

Although the risk of adverse clinical events is higher in patients with preoperative renal dysfunction, that of internal thoracic artery and saphenous vein graft failure is not. This suggests that factors other than graft failure account for the worse clinical outcomes in this high-risk cohort. Further studies are needed to identify other mechanisms of these worse outcomes so that appropriate measures can be developed to improve long-term outcomes in patients with renal dysfunction undergoing coronary artery bypass surgery.

Abbreviations and Acronyms: CABG, coronary artery bypass graft, CK, creatine kinase, ITA, internal thoracic artery, MI, myocardial infarction, PREVENT-IV, PRoject of Ex-vivo Vein Graft Engineering via Transfection-IV, SVG, saphenous vein graft, ULN, upper limit of normal

CTSNet classification: 23

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The Prevent-IV trial was funded by Corgentech Inc, South San Francisco, Calif. Dr Mehta is funded by the Duke Clinical Research Institute, Durham, NC.

PII: S0022-5223(08)01090-8

doi:10.1016/j.jtcvs.2008.02.085

The Journal of Thoracic and Cardiovascular Surgery
Volume 136, Issue 5 , Pages 1149-1155, November 2008